Literature DB >> 2308150

Synthesis, conformation, and immunosuppressive activities of three analogues of cyclosporin A modified in the 1-position.

J D Aebi1, D T Deyo, C Q Sun, D Guillaume, B Dunlap, D H Rich.   

Abstract

The syntheses of three new cyclosporin A (CsA) analogues that contain novel MeBmt derivatives in the 1-position are described. The MeBmt analogue that contains an additional methyl group on C4, (2S,3R,6E)-4,4-dimethyl-3-hydroxy-2-(N-methylamino)-6-octenoic acid (MeBm2t), was synthesized in four steps beginning with the reaction of Pmz-Sar-OtBu with (4E)-2,2-dimethyl-4-hexenal. The C4 desmethyl analogue of MeBmt, (2S,3R,6E)-3-hydroxy-2-(N-methylamino)-6-octenoic acid (MeBth), was synthesized in nine steps by a route based on the Sharpless chiral epoxidation procedure. The alkynyl derivative of MeBmt, (2S,3R,4R)-4-methyl-3-hydroxy-2-(N-methylamino)-6-octynoic acid (MeByt), was synthesized by a modification of the procedure described by Tung et al. for the synthesis of MeBmt. Each MeBmt analogue was protected as the N,O-acetonide and coupled with the hexapeptide Abu-Sar-MeLeu-Val-MeLeu-Ala-OBzl. The resulting heptapeptide was deprotected and coupled with Fmoc-D-Ala-MeLeu-MeLeu-MeVal-OH. The resulting undecapeptides were deprotected and cyclized to give the corresponding CsA analogues. Conformational analysis by 1D and 2D NMR methods was carried out for each analogue in chloroform, and the results are compared with the corresponding solution conformations of CsA and dihydrocyclosporin. The immunosuppressive activities of each analogue, determined in concanavalin A stimulated thymocytes, are lower than obtained for CsA. The results establish the important effect the methyl group and the double bond in MeBmt have on the solution conformation of the 1-position residue in CsA and on immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308150     DOI: 10.1021/jm00165a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology.

Authors:  J A Silverman; M L Hayes; B J Luft; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  The importance of structural factors on the rate and the extent of N,O-acyl migration in cyclic and linear peptides.

Authors:  R Oliyai; T J Siahaan; V J Stella
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

Review 3.  Enatiomerically pure hydroxycarboxylic acids: current approaches and future perspectives.

Authors:  Qun Ren; Katinka Ruth; Linda Thöny-Meyer; Manfred Zinn
Journal:  Appl Microbiol Biotechnol       Date:  2010-06       Impact factor: 4.813

4.  Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A.

Authors:  S R Bartz; E Hohenwalter; M K Hu; D H Rich; M Malkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

5.  Rubipodanin A, the First Natural N-Desmonomethyl Rubiaceae-Type Cyclopeptide from Rubia podantha, Indicating an Important Role of the N9-Methyl Group in the Conformation and Bioactivity.

Authors:  Zhe Wang; Si-Meng Zhao; Li-Mei Zhao; Xiao-Qiang Chen; Guang-Zhi Zeng; Ning-Hua Tan
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

6.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

7.  Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?

Authors:  N H Sigal; F Dumont; P Durette; J J Siekierka; L Peterson; D H Rich; B E Dunlap; M J Staruch; M R Melino; S L Koprak
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

8.  Cyclophilin inhibitors as antiviral agents.

Authors:  Michael Peel; Andrew Scribner
Journal:  Bioorg Med Chem Lett       Date:  2013-06-10       Impact factor: 2.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.